Hera Fertility has launched SmartScore, an artificial intelligence tool that converts standard semen analysis results into a numerical fertility probability score on a scale of 1 to 100, giving men and their clinicians a more interpretable output than the raw parameter values produced by conventional semen analysis. The tool applies machine learning models trained on semen analysis data and fertility outcome records to generate a probability score that represents the likelihood of natural conception based on the full combination of measured parameters rather than any single value in isolation.
Standard semen analysis measures sperm count, concentration, motility, and morphology, producing numerical values for each parameter that are compared against reference ranges established by the World Health Organization. That comparison tells a clinician whether individual parameters fall within or outside the normal range, but does not produce an integrated assessment of how those parameters interact to influence actual fertility probability. A man with borderline results across multiple parameters may receive individual parameter readings that each fall near the normal threshold, leaving both the clinician and the patient without a clear picture of what the combined profile means for the likelihood of conception.
SmartScore addresses that interpretive gap by processing the full parameter set through a predictive model and expressing the output as a single number. A score of 75, for example, reflects a meaningfully different fertility probability than a score of 35, in an immediately understandable format that does not require the patient to interpret multiple clinical reference ranges simultaneously. For men navigating fertility assessment for the first time, that clarity reduces the confusion that frequently accompanies the standard analysis report and supports more informed conversations between patients and their healthcare providers.
"Semen analysis has been the standard tool for male fertility evaluation for decades, but the output has always required clinical interpretation that most patients aren't equipped to do on their own," said Thiv Paramsothy, Founder of Hera Fertility. "SmartScore takes the same underlying data and converts it into something that actually communicates fertility probability in plain terms. A number from 1 to 100 is something a patient can understand and act on. That clarity changes the quality of the conversation between the patient and their doctor."
The SmartScore tool processes semen analysis results submitted through Hera Fertility's platform, generating a probability score alongside a breakdown of which parameters contributed most significantly to the overall assessment. That parameter-level transparency allows clinicians to identify the specific components of a patient's profile that are driving a low score and target interventions accordingly. For patients with scores that suggest reduced fertility probability, the breakdown provides a starting point for clinical discussion about whether lifestyle modification, medical treatment, or assisted reproduction options are the appropriate next step. Hera Fertility's platform is designed to complement clinical judgment rather than replace it, with SmartScore positioned as a decision-support tool within the broader fertility assessment process. The company recently advanced toward clinical validation through its selection for the Mayo Clinic Platform Accelerate program, which will assess SmartScore's predictive accuracy against outcomes data from Mayo Clinic's clinical dataset.
Hera Fertility provides semen analysis results interpretation through its platform for patients accessing the tool directly, as well as through clinic partnerships where SmartScore is integrated into the standard fertility workup process. The direct-to-patient access model allows men to submit their existing semen analysis results without requiring a new clinical appointment, receiving a SmartScore that they can bring to a consultation with their own physician or fertility specialist. That pathway reduces the delay between initial analysis and informed clinical discussion for patients who have already completed testing but are still working to understand what their results mean.
The company also serves the Los Angeles fertility market, where a high concentration of fertility clinics and a demographically diverse patient population make it a strategically important geography for the SmartScore rollout. Access to semen analysis in Los Angeles through Hera Fertility's platform provides patients in that market with the same interpretive tool available through the company's other clinical partnerships, supporting the consistent application of the SmartScore methodology across different regional markets and patient populations.
About Hera Fertility: Hera Fertility is a health technology company founded by Thiv Paramsothy, developing AI-driven assessment tools for male fertility evaluation. The company's SmartScore tool converts semen analysis data into a 1 to 100 fertility probability score, providing men and their clinicians with an integrated, interpretable fertility assessment. Hera Fertility has been selected for the Mayo Clinic Platform Accelerate program for clinical validation of its AI models and provides semen analysis interpretation services across North America.
###
For more information about Hera Fertility, contact the company here:
Hera Fertility
Thiv Paramsothy
(888) 850-0919
support@herafertility.co
1178 Broadway, 3rd floor, 3092, New York, NY 10001, United States
